PTGER4 and breast carcinoma: In murine breast cancer models, EP4 antagonism has been shown to reduce primary tumor growth, stem cell-like functions, tumor-associated angiogenesis and lymphangiogenesis, and metastasis to the lymph nodes and lungs [45,46].